Efficiency of local BCNU in newly diagnosed and recurrent glioblastoma and MGMT promoter methylation

A. Gutenberg, H.C. Bock, V. Rohde, G. Reifenberger & A. Giese
Objective: There is reason to believe that alternative dose-dense schedules may overcome resistance in patients with an unmethylated MGMT promoter. Carmustine (BCNU) is a nitrosourea derivate which alkylates DNA and RNA, but it does not render cells cross resistant to other alkylators and therefore [for full text, please go to the a.m. URL]